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In today’s Lancet, Professor Strnad and colleagues present 5-year results of a large, international 
randomised trial testing standard whole breast radiotherapy (WBI) against accelerated partial breast 
irradiation (APBI) after breast conserving surgery, in a selected lower risk population of women. The 
APBI technique involved a 4-5-day postoperative course of radiotherapy delivered via radioactive 
sources inserted into breast tissue surrounding the operation site, the so-called tumour bed. The 
study design tested for non-inferiority with a primary endpoint of local recurrence in 1184 patients 
recruited from 16 centres and the 5-year local recurrence rates were <2% in both arms. A predefined 
3% non-inferiority margin was upheld by a difference in local relapse rates of 0.53% (95% CI: -0.72 – 
1.75%) in favour of WBI. There were no statistical differences in disease-free or overall survival, and 
adverse effects were similarly mild in both groups.  
 
So what is the background to APBI? Firstly, it is not a new concept. The first randomised trials 
comparing APBI with WBI began in the 1980’s with the observation that the majority of breast 
cancers recur close to the original tumour bed. Therefore, it was hypothesised that treating this 
region alone may reduce side effects with no detriment in local control. An added bonus could be 
less treatments and a shorter overall treatment time. Unfortunately, these early pioneering trials 
showed an unacceptable increase in local recurrence rates, probably due to inadequate patient 
selection and less sophisticated radiotherapy techniques.  
 
A resurgence of enthusiasm for APBI returned around a decade ago, coinciding with rapid 
improvements in radiotherapy techniques, and a flurry of new randomised trials were launched. The 
APBI techniques were heterogeneous, including some that placed radioactive sources into the 
tumour bed itself and others that used external radiation delivered via a linear accelerator. In 
addition, there was considerable variation in both the volume of breast tissue treated and the dose 
delivered. A recent systematic overview of APBI, albeit with inclusion of the older studies, 
demonstrated excess local recurrence compared with WBI1. The Forest plot of hazard ratios (HR) for 
local recurrence from this publication are displayed in figure 1, demonstrating HRs as high as 7. 
 
So how does the trial from Strad and colleagues compare with others? It is a welcome relief to 
comment on a carefully designed and conducted trial, presented and discussed in a measured 
fashion. Primary analysis at a median follow up of 6.6 years using Kaplan-Meier statistics has been 
carried out “as treated”, which is appropriate for a non-inferiority trial2. The 3% non-relevant, non-
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inferiority threshold settled upon by the investigators looks large in the light of dramatic falls in local 
recurrence rates since study inception, but the current absolute difference is acceptable by any 
standards. The research team also acknowledge the importance of continuing follow up for at least 
10 years and this is essential given the linear rate of recurrence for lower risk patients and the on-
going effect of radiotherapy after 5 years of the treatment.  
 
The authors suggest that their technique is superior to APBI delivered with a linear accelerator by 
highlighting the 3-year results of the RAPID study, which showed high rates of adverse cosmesis3. 
This is very likely to be due to the radiation dose schedule, as the “equivalent” dose in standard 2Gy 
daily treatments is far higher than that used routinely for WBI4. In contrast, the UK IMPORT LOW 
APBI trial uses a standard radiation dose across all arms and the 5-year results will be reported in 
20165. 
 
So does this trial herald the death knell for WBI with APBI becoming the new standard? We think 
not. This trial presents maturing data and further evidence is required from the 14,000 patients in 5 
unreported APBI phase III trials. Furthermore, possible attractions of APBI such as short overall 
treatment time and decreased heart dose are now reflected with modern WBI. The 10-year results 
of UK and Canadian trials comparing 5 versus 3 weeks of WBI show that local control is equivalent, 
but side effects are reduced with the 3-week treatment6,7. The UK Fast Forward study is going 
further and investigating just 5 treatments for WBI over one week8. In addition, recent advantages in 
cardiac-sparing WBI techniques have reduced the heart dose dramatically9.  
 
So how does this trial fit with the future for breast radiotherapy? We know that breast cancer 
represents a spectrum of different diseases with variation in prognosis and radiotherapy is no longer 
“one size fits all”, but ranges from highly complex treatments to the breast and regional lymph 
nodes, to complete avoidance of any radiation. It is likely that APBI will have a place within this array 
of treatments. The challenge will be to select the most appropriate treatment for the individual 
patient and personalise radiotherapy based on tumour biology10. 
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